We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Glaucoma Treatment Market

Schedule a Call

Glaucoma Treatment Market

Glaucoma Treatment Market (Product Type - Prostaglandin Analogs (PGAs), Alpha Agonist, Beta Blockers, Cholinergic, Carbonic Anhydrase Inhibitors, and Combined Medications; Indication - Angle Closure Glaucoma (ACG), Open Angle Glaucoma (OAG), Secondary Glaucoma, Congenital Glaucoma, and Other Indications; Sales Channel - Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026

Glaucoma is considered to be the second most cause for blindness around the world, according to WHO. This leading reason for preventable blindness is associated with chronic progressive optic neuropathy, which leads to irreversible vision loss via damage to optic nerve. No treatments currently exist for directly preventing glaucoma, however several commercially available therapies concentrate on curtailing elevated intraocular pressure, which is a known risk factor responsible for the development and progression of glaucoma.

Glaucoma Treatment Market to Enter a New Phase of Expansion

Demand for glaucoma treatment is expected to be significantly driven by the advent of fixed-dose combination products that combine drugs from various classes. The market for glaucoma treatment will enter a new phase of expansion, with the introduction of first-in-class, innovative drugs such as trabodenoson, Vesneo, and Roclatan/Rhopressa. Prevalence of glaucoma is increasing in parallel with the rise in geriatric population worldwide, as older individuals are relatively more prone to developing glaucoma. In addition, mounting number of people with diabetes and those with family history of glaucoma also contribute to this disease prevalence significantly. Governments and healthcare institutions are increasingly taking initiatives to spread the awareness about treatment options available for patients with glaucoma.

Product development strategies in the recent past have been impressive with surgery options, with several effective additions such as photodynamic therapy and laser therapy. However, excellent efficiency and efficacy of currently available drugs, particularly carbonic anhydrase inhibitors and prostaglandin analogs, have set barriers to the development of new therapy options.

global glaucoma treatment market

A new exhaustive report collated by Transparency Market Research envisages an average growth for the global glaucoma treatment market in the period between 2017 and 2026.More than US$ 3,300 revenues are expected to be gained from treatment of glaucoma across the globe by 2026-end.

North America to Remain Leading Revenue Contributor to Global Glaucoma Treatment Market

Incidences of glaucoma in North American countries are rising significantly, with the surge in older population in the region, thereby creating high demand for glaucoma drugs. Demand for glaucoma drugs in the region is fulfilled owing to the presence of several pharmaceutical giants and heavy investments in pharmaceutical sector. In addition, the economic vigour and enormous investments in healthcare sector in North America have meant that the region will remain the leading revenue contributor to the global glaucoma treatment market. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to be major revenue contributors to the market during the forecast period.

Prostaglandin analogs (PGAs) seek extensive adoption for treating OAG, owing to their relatively higher effectiveness. Among several types of prostaglandin analogs introduced in the market, administration of latanoprost, travoprost, and tafluprost has represented a comparatively more significant IOP-lowering ability in clinical trials. All these factors have made prostaglandin analogs to be highly sought-after among products available for glaucoma treatment. Alpha agonist will also prevail as a remunerative product in the glaucoma treatment market.

Key Research Findings from the Report

  • Hospital pharmacies will remain dominant among sales channels in the glaucoma treatment market
  • Angle closure glaucoma (ACG) are expected to be the most prevalent indication of glaucoma in the market during 2017 to 2026

Competition Tracking

The global market for glaucoma treatment is crowded with branded drugs coupled with surging number of generics, which in turn is creating significant competition in the market. This has further set limits to introduction of novel therapies, along with several products being due to lose exclusivity. Late-stage pipeline for glaucoma, however, holds promise for treatments imparting novel mechanisms of action, thereby creating lucrative growth opportunities for the market players. Key players underpinning growth of the global glaucoma treatment market include Novartis AG, Allergan, Merck & Co., Inc., Akorn, Inc., Bausch & Lomb Incorporated, Teva Pharmaceuticals, Pfizer, Santen, Aerie Pharmaceuticals, and Inotek Pharmaceuticals.

Increasing Demand for Efficient Prescription Eye Drops Drive Glaucoma Treatment Market

Manufacturers and players in the glaucoma treatment market are focused on developing newer drug combinations and prescription eye drops to control glaucoma at a primary stage. Multiple bio-medical and pharmaceutical companies are investing in product development to develop effective drugs that can relieve the burden on healthcare facilities. Some of the drugs used for treatment of glaucoma include prostaglandin analogs or PGAs, beta blockers, carbonic anhydrase inhibitors, alpha agonists, and cholinergic, as well as certain types of combination medicines. These drugs help in lowering the intraocular pressure by increasing the drainage of fluid from the patient’s eye. However, instances of drug recall by major industry players can hamper the growth of global glaucoma treatment market in coming years. Failure to meet the regulatory standards and noticeable impurities in various drug combinations are key factors behind these product recalls. Failure to meet regulatory standards is noticed to generate fear and skepticism in both patients and healthcare professionals.

Alternative techniques that require little medication and offer prolonged relief can promise potential growth in glaucoma treatment market in coming years. Some of the alternative techniques used for treatment of glaucoma include laser treatment known as selective laser trabeculoplasty and minimally invasive glaucoma surgeries, also known as MIGs. Both of these techniques also aim at reducing the intraocular pressure by stimulating an increased fluid outflow from the patient’s eye. However, the global pandemic caused by the outbreak of novel coronavirus has caused a slowdown in patients opting for SLTs and MIGs. As many countries have categorized glaucoma as ‘elective’, patients are preferring using medications and prescription eye drops to slow down the progression of glaucoma. Many patients are postponing their elective glaucoma surgeries for the time being and in turn, looking for newer and advanced medication solutions for the treatment of glaucoma. This trend is anticipated to boost the glaucoma treatment market in near future.

Market Taxonomy

A segmentation analysis delivered in the report submits insights on the global market for glaucoma treatment. The market is characterized based on sales channel, indication, product type, and region. Analyses on the Y-o-Y growth comparison, market share comparison, and the revenue comparison in accordance with relevant market numbers has been delivered in this chapter. The global market for glaucoma treatment has been divided regionally into Asia-Pacific excluding Japan, Europe, Middle East & Africa, Japan, Latin America, and North America.

Region
  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Product Type
  • Prostaglandin Analogs (PGAs)
  • Alpha Agonist
  • Beta Blockers
  • Cholinergic
  • Carbonic Anhydrase Inhibitors
  • Combined Medications

Indication
  • Angle Closure Glaucoma (ACG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma
  • Other Indications

Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

    1. Global Economic Outlook

    2. Global Glaucoma Treatment Market - Executive Summary

    3. Global Glaucoma Treatment Market Overview
         3.1. Introduction
                3.1.1. Global Glaucoma Treatment Market Taxonomy
                3.1.2. Global Glaucoma Treatment Market Definition
         3.2. Global Glaucoma Treatment Market Size (US$ Mn) and Forecast, 2012-2026
                3.2.1. Global Glaucoma Treatment Market Y-o-Y Growth
         3.3. Global Glaucoma Treatment Market Dynamics
         3.4. Supply Chain
         3.5. Cost Structure
         3.6. Pricing Analysis 
         3.7. PEST Analysis
         3.8. Leading Cause for Blindness and Visual Impairment Globally 
         3.9. Product Approval and Launches for Glaucoma Treatment
         3.10. Common Side Effects and Precautions of Glaucoma Drugs
         3.11. Glaucoma Drug Patent Analysis
         3.12. Investment Feasibility Assessment
         3.13. Porter’s Five Forces Analysis
         3.14. List of Distributors/Retailers/Online Sellers
         3.15. Key Participants Market Presence (Intensity Map) By Region

    4. Global Glaucoma Treatment Market Analysis and Forecast 2012-2026 
         4.1. Global Glaucoma Treatment Market Size and Forecast By Product Type, 2012-2026
                4.1.1. Prostaglandin Analogs (PGAs) Market Size and Forecast, 2012-2026
                         4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.1.2. Market Share Comparison, By Region
                         4.1.1.3. Y-o-Y growth Comparison, By Region
                4.1.2. Alpha Agonist Market Size and Forecast, 2012-2026
                         4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.2.2. Market Share Comparison, By Region
                         4.1.2.3. Y-o-Y growth Comparison, By Region
                4.1.3. Beta Blockers Market Size and Forecast, 2012-2026
                         4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.3.2. Market Share Comparison, By Region
                         4.1.3.3. Y-o-Y growth Comparison, By Region
                4.1.4. Cholinergic Market Size and Forecast, 2012-2026
                         4.1.4.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.4.2. Market Share Comparison, By Region
                         4.1.4.3. Y-o-Y growth Comparison, By Region
                4.1.5. Carbonic Anhydrase Inhibitors Market Size and Forecast, 2012-2026
                         4.1.5.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.5.2. Market Share Comparison, By Region
                         4.1.5.3. Y-o-Y growth Comparison, By Region
                4.1.6. Combined Medications Market Size and Forecast, 2012-2026
                         4.1.6.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.6.2. Market Share Comparison, By Region
                         4.1.6.3. Y-o-Y growth Comparison, By Region
         4.2. Global Glaucoma Treatment Market Size and Forecast By Indication, 2012-2026
                4.2.1. Angle Closure Glaucoma (ACG) Market Size and Forecast, 2012-2026
                         4.2.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.1.2. Market Share Comparison, By Region
                         4.2.1.3. Y-o-Y growth Comparison, By Region
                4.2.2. Open Angle Glaucoma (OAG) Market Size and Forecast, 2012-2026
                         4.2.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.2.2. Market Share Comparison, By Region
                         4.2.2.3. Y-o-Y growth Comparison, By Region
                4.2.3. Secondary Glaucoma Market Size and Forecast, 2012-2026
                         4.2.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.3.2. Market Share Comparison, By Region
                         4.2.3.3. Y-o-Y growth Comparison, By Region
                4.2.4. Congenital Glaucoma Market Size and Forecast, 2012-2026
                         4.2.4.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.4.2. Market Share Comparison, By Region
                         4.2.4.3. Y-o-Y growth Comparison, By Region
                4.2.5. Other Indications Market Size and Forecast, 2012-2026
                         4.2.5.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.5.2. Market Share Comparison, By Region
                         4.2.5.3. Y-o-Y growth Comparison, By Region
         4.3. Global Glaucoma Treatment Market Size and Forecast By Sales Channel, 2012-2026
                                     4.3.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
                         4.3.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.1.2. Market Share Comparison, By Region
                         4.3.1.3. Y-o-Y growth Comparison, By Region
                4.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
                         4.3.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.2.2. Market Share Comparison, By Region
                         4.3.2.3. Y-o-Y growth Comparison, By Region
                4.3.3. Online Sales Market Size and Forecast, 2012-2026
                         4.3.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.3.2. Market Share Comparison, By Region
                         4.3.3.3. Y-o-Y growth Comparison, By Region

    5. North America Glaucoma Treatment Market Size and Forecast, 2012-2026
         5.1. North America Outlook 
         5.2. North America Parent Market Outlook 
         5.3. North America Target Market Outlook 
         5.4. Revenue (US$ Mn) Comparison, By Country 
                5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
                5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
         5.5. Revenue (US$ Mn) Comparison, By Product Type 
         5.6. Revenue (US$ Mn) Comparison, By Indication 
         5.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    6. Latin America Glaucoma Treatment Market Size and Forecast, 2012-2026
         6.1. Latin America Outlook 
         6.2. Latin America Parent Market Outlook 
         6.3. Latin America Target Market Outlook 
         6.4. Revenue (US$ Mn) Comparison, By Country 
                6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
                6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
                6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
         6.5. Revenue (US$ Mn) Comparison, By Product Type 
         6.6. Revenue (US$ Mn) Comparison, By Indication 
         6.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    7. Europe Glaucoma Treatment Market Size and Forecast, 2012-2026
         7.1. Europe Outlook 
         7.2. Europe Parent Market Outlook 
         7.3. Europe Target Market Outlook 
         7.4. Revenue (US$ Mn) Comparison, By Country 
                7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
                7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
                7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
                7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
                7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
                7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
         7.5. Revenue (US$ Mn) Comparison, By Product Type 
         7.6. Revenue (US$ Mn) Comparison, By Indication 
         7.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    8. Japan Glaucoma Treatment Market Size and Forecast, 2012-2026
         8.1. Japan Outlook 
         8.2. Japan Parent Market Outlook 
         8.3. Japan Target Market Outlook 
         8.4. Japan  Market Size and Forecast (US$ Mn), 2012-2026
         8.5. Revenue (US$ Mn) Comparison, By Product Type 
         8.6. Revenue (US$ Mn) Comparison, By Indication 
         8.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    9. APEJ Glaucoma Treatment Market Size and Forecast, 2012-2026
         9.1. APEJ Outlook 
         9.2. APEJ Parent Market Outlook 
         9.3. APEJ Target Market Outlook 
         9.4. Revenue (US$ Mn) Comparison, By Country 
                9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
                9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
                9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
                9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
                9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
                9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
         9.5. Revenue (US$ Mn) Comparison, By Product Type 
         9.6. Revenue (US$ Mn) Comparison, By Indication 
         9.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    10. MEA Glaucoma Treatment Market Size and Forecast, 2012-2026
         10.1. MEA Outlook 
         10.2. MEA Parent Market Outlook 
         10.3. MEA Target Market Outlook 
         10.4. Revenue (US$ Mn) Comparison, By Country 
                10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
                10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
                10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
                10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
         10.5. Revenue (US$ Mn) Comparison, By Product Type 
         10.6. Revenue (US$ Mn) Comparison, By Indication 
         10.7. Revenue (US$ Mn) Comparison, By Sales Channel 

    11. Global Glaucoma Treatment Market Company Share, Competition Landscape and Company Profiles
         11.1. Global Glaucoma Treatment Market Company Share  
         11.2. Global Glaucoma Treatment Market Competition Landscape
         11.3. Global Glaucoma Treatment Market Company Profiles
                11.3.1. Novartis AG

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.2. Pfizer, Inc.

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.3. Merck & Co, Inc.

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.4. Bausch & Lomb Incorporated 

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.5. Allergan Plc

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.6. Perrigo Co. Plc

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.7. Teva Pharmaceutical Industries Limited

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.8. Akorn, Inc.

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

                11.3.9. Mobius Therapeutics, LLC

    • Overview
    • Offering Portfolio
    • Production Footprint
    • Sales Footprint
    • Channel Footprint
    • Strategy Outlook
      • Sales Strategy
      • Channel Strategy
      • Marketing Strategy

    12. Research Methodology

    13. Disclaimer

    List of Table

    TABLE 1 Global Glaucoma Treatment Market Value (US$ Mn), 2012-2017
    TABLE 2 Global Glaucoma Treatment Market Value (US$ Mn), 2018-2026
    TABLE 3 Global Glaucoma Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
    TABLE 4 Global Prostaglandin Analogs (PGAs) Segment Value (US$ Mn), By Region 2012-2017
    TABLE 5 Global Prostaglandin Analogs (PGAs) Segment Value (US$ Mn), By Region 2018-2026
    TABLE 6 Global Prostaglandin Analogs (PGAs) Segment Market Share, By Region 2012-2017
    TABLE 7 Global Prostaglandin Analogs (PGAs) Segment Market Share, By Region 2018-2026
    TABLE 8 Global Prostaglandin Analogs (PGAs) Segment Y-o-Y, By Region 2017-2026
    TABLE 9 Global Alpha Agonist Segment Value (US$ Mn), By Region 2012-2017
    TABLE 10 Global Alpha Agonist Segment Value (US$ Mn), By Region 2018-2026
    TABLE 11 Global Alpha Agonist Segment Market Share, By Region 2012-2017
    TABLE 12 Global Alpha Agonist Segment Market Share, By Region 2018-2026
    TABLE 13 Global Alpha Agonist Segment Y-o-Y, By Region 2017-2026
    TABLE 14 Global Beta Blockers Segment Value (US$ Mn), By Region 2012-2017
    TABLE 15 Global Beta Blockers Segment Value (US$ Mn), By Region 2018-2026
    TABLE 16 Global Beta Blockers Segment Market Share, By Region 2012-2017
    TABLE 17 Global Beta Blockers Segment Market Share, By Region 2018-2026
    TABLE 18 Global Beta Blockers Segment Y-o-Y, By Region 2017-2026
    TABLE 19 Global Cholinergic Segment Value (US$ Mn), By Region 2012-2017
    TABLE 20 Global Cholinergic Segment Value (US$ Mn), By Region 2018-2026
    TABLE 21 Global Cholinergic Segment Market Share, By Region 2012-2017
    TABLE 22 Global Cholinergic Segment Market Share, By Region 2018-2026
    TABLE 23 Global Cholinergic Segment Y-o-Y, By Region 2017-2026
    TABLE 24 Global Carbonic Anhydrase Inhibitors Segment Value (US$ Mn), By Region 2012-2017
    TABLE 25 Global Carbonic Anhydrase Inhibitors Segment Value (US$ Mn), By Region 2018-2026
    TABLE 26 Global Carbonic Anhydrase Inhibitors Segment Market Share, By Region 2012-2017
    TABLE 27 Global Carbonic Anhydrase Inhibitors Segment Market Share, By Region 2018-2026
    TABLE 28 Global Carbonic Anhydrase Inhibitors Segment Y-o-Y, By Region 2017-2026
    TABLE 29 Global Combined Medications Segment Value (US$ Mn), By Region 2012-2017
    TABLE 30 Global Combined Medications Segment Value (US$ Mn), By Region 2018-2026
    TABLE 31 Global Combined Medications Segment Market Share, By Region 2012-2017
    TABLE 32 Global Combined Medications Segment Market Share, By Region 2018-2026
    TABLE 33 Global Combined Medications Segment Y-o-Y, By Region 2017-2026
    TABLE 34 Global Angle Closure Glaucoma (ACG) Segment Value (US$ Mn), By Region 2012-2017
    TABLE 35 Global Angle Closure Glaucoma (ACG) Segment Value (US$ Mn), By Region 2018-2026
    TABLE 36 Global Angle Closure Glaucoma (ACG) Segment Market Share, By Region 2012-2017
    TABLE 37 Global Angle Closure Glaucoma (ACG) Segment Market Share, By Region 2018-2026
    TABLE 38 Global Angle Closure Glaucoma (ACG) Segment Y-o-Y, By Region 2017-2026
    TABLE 39 Global Open Angle Glaucoma (OAG) Segment Value (US$ Mn), By Region 2012-2017
    TABLE 40 Global Open Angle Glaucoma (OAG) Segment Value (US$ Mn), By Region 2018-2026
    TABLE 41 Global Open Angle Glaucoma (OAG) Segment Market Share, By Region 2012-2017
    TABLE 42 Global Open Angle Glaucoma (OAG) Segment Market Share, By Region 2018-2026
    TABLE 43 Global Open Angle Glaucoma (OAG) Segment Y-o-Y, By Region 2017-2026
    TABLE 44 Global Secondary Glaucoma Segment Value (US$ Mn), By Region 2012-2017
    TABLE 45 Global Secondary Glaucoma Segment Value (US$ Mn), By Region 2018-2026
    TABLE 46 Global Secondary Glaucoma Segment Market Share, By Region 2012-2017
    TABLE 47 Global Secondary Glaucoma Segment Market Share, By Region 2018-2026
    TABLE 48 Global Secondary Glaucoma Segment Y-o-Y, By Region 2017-2026
    TABLE 49 Global Congenital Glaucoma Segment Value (US$ Mn), By Region 2012-2017
    TABLE 50 Global Congenital Glaucoma Segment Value (US$ Mn), By Region 2018-2026
    TABLE 51 Global Congenital Glaucoma Segment Market Share, By Region 2012-2017
    TABLE 52 Global Congenital Glaucoma Segment Market Share, By Region 2018-2026
    TABLE 53 Global Congenital Glaucoma Segment Y-o-Y, By Region 2017-2026
    TABLE 54 Global Other Indications Segment Value (US$ Mn), By Region 2012-2017
    TABLE 55 Global Other Indications Segment Value (US$ Mn), By Region 2018-2026
    TABLE 56 Global Other Indications Segment Market Share, By Region 2012-2017
    TABLE 57 Global Other Indications Segment Market Share, By Region 2018-2026
    TABLE 58 Global Other Indications Segment Y-o-Y, By Region 2017-2026
    TABLE 59 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 60 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 61 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 62 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 63 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 64 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 65 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 66 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 67 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 68 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 69 Global Online Sales Segment Value (US$ Mn), By Region 2012-2017
    TABLE 70 Global Online Sales Segment Value (US$ Mn), By Region 2018-2026
    TABLE 71 Global Online Sales Segment Market Share, By Region 2012-2017
    TABLE 72 Global Online Sales Segment Market Share, By Region 2018-2026
    TABLE 73 Global Online Sales Segment Y-o-Y, By Region 2017-2026
    TABLE 74 North America Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 75 North America Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 76 North America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 77 North America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 78 North America Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 79 North America Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 80 North America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 81 North America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    TABLE 82 Latin America Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 83 Latin America Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 84 Latin America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 85 Latin America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 86 Latin America Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 87 Latin America Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 88 Latin America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 89 Latin America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    TABLE 90 Europe Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 91 Europe Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 92 Europe Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 93 Europe Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 94 Europe Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 95 Europe Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 96 Europe Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 97 Europe Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    TABLE 98 Japan Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 99 Japan Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 100 Japan Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 101 Japan Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 102 Japan Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 103 Japan Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 104 Japan Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 105 Japan Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    TABLE 106 APEJ Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 107 APEJ Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 108 APEJ Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 109 APEJ Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 110 APEJ Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 111 APEJ Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 112 APEJ Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 113 APEJ Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    TABLE 114 MEA Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    TABLE 115 MEA Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    TABLE 116 MEA Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    TABLE 117 MEA Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    TABLE 118 MEA Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    TABLE 119 MEA Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    TABLE 120 MEA Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    TABLE 121 MEA Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026

    List of Figure

    FIG. 1 Global Glaucoma Treatment Market Value (US$ Mn), 2012-2017
    FIG. 2 Global Glaucoma Treatment Market Value (US$ Mn) Forecast, 2018-2026
    FIG. 3 Global Glaucoma Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
    FIG. 4 Global Prostaglandin Analogs (PGAs) Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 5 Global Prostaglandin Analogs (PGAs) Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 6 Global Prostaglandin Analogs (PGAs) Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 7 Global Alpha Agonist Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 8 Global Alpha Agonist Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 9 Global Alpha Agonist Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 10 Global Beta Blockers Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 11 Global Beta Blockers Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 12 Global Beta Blockers Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 13 Global Cholinergic Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 14 Global Cholinergic Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 15 Global Cholinergic Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 16 Global Carbonic Anhydrase Inhibitors Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 17 Global Carbonic Anhydrase Inhibitors Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 18 Global Carbonic Anhydrase Inhibitors Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 19 Global Combined Medications Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 20 Global Combined Medications Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 21 Global Combined Medications Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 22 Global Angle Closure Glaucoma (ACG) Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 23 Global Angle Closure Glaucoma (ACG) Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 24 Global Angle Closure Glaucoma (ACG) Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 25 Global Open Angle Glaucoma (OAG) Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 26 Global Open Angle Glaucoma (OAG) Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 27 Global Open Angle Glaucoma (OAG) Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 28 Global Secondary Glaucoma Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 29 Global Secondary Glaucoma Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 30 Global Secondary Glaucoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 31 Global Congenital Glaucoma Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 32 Global Congenital Glaucoma Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 33 Global Congenital Glaucoma Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 34 Global Other Indications Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 35 Global Other Indications Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 36 Global Other Indications Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 37 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 38 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 39 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 40 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 41 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 42 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 43 Global Online Sales Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 44 Global Online Sales Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 45 Global Online Sales Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 46 North America Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 47 North America Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 48 North America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 49 North America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 50 North America Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 51 North America Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 52 North America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 53 North America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    FIG. 54 Latin America Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 55 Latin America Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 56 Latin America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 57 Latin America Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 58 Latin America Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 59 Latin America Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 60 Latin America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 61 Latin America Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    FIG. 62 Europe Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 63 Europe Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 64 Europe Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 65 Europe Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 66 Europe Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 67 Europe Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 68 Europe Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 69 Europe Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    FIG. 70 Japan Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 71 Japan Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 72 Japan Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 73 Japan Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 74 Japan Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 75 Japan Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 76 Japan Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 77 Japan Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    FIG. 78 APEJ Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 79 APEJ Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 80 APEJ Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 81 APEJ Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 82 APEJ Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 83 APEJ Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 84 APEJ Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 85 APEJ Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026
    FIG. 86 MEA Glaucoma Treatment Market Value (US$ Mn), By Country 2012-2017
    FIG. 87 MEA Glaucoma Treatment Market Value (US$ Mn), By Country 2018-2026
    FIG. 88 MEA Glaucoma Treatment Market Value (US$ Mn), By Product Type 2012-2017
    FIG. 89 MEA Glaucoma Treatment Market Value (US$ Mn), By Product Type 2018-2026
    FIG. 90 MEA Glaucoma Treatment Market Value (US$ Mn), By Indication 2012-2017
    FIG. 91 MEA Glaucoma Treatment Market Value (US$ Mn), By Indication 2018-2026
    FIG. 92 MEA Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2012-2017
    FIG. 93 MEA Glaucoma Treatment Market Value (US$ Mn), By Sales Channel 2018-2026

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved